Vera Therapeutics (Nasdaq: VERA) reported that its Board Compensation Committee granted Nasdaq Listing Rule 5635(c)(4) inducement equity awards under the 2024 Inducement Plan on August 3–4, 2026. The grants include non-qualified stock options for 63,011 shares and RSUs for 44,987 shares to new Chief Regulatory Officer Nancy Bowman, M.D., Ph.D., and options for 5,600 shares plus RSUs for 2,800 shares to two new employees.
Options granted on August 3 have an exercise price of $32.23 per share, and those granted on August 4 have a $29.95 exercise price. Options vest over four years with 25% after one year and the remainder monthly over 36 months. RSUs vest 25% annually on each August 20 over four years, all subject to continued service and award agreements.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Explained
The August 3–4 grants are awards whose disclosed share amounts remain subject to multi-year vesting and continued service, rather than being presented as immediately vested shares.
Market Context
The two prior inducement-grant announcements in the record were followed by -1.19% and -1.67% 24-hou...
Analysis
The two prior inducement-grant announcements in the record were followed by -1.19% and -1.67% 24-hour reactions. That history contextualizes this event, while insider Net Selling remains an additional risk.
Key Figures
August 3 stock options:63,011 sharesAugust 3 RSUs:44,987 sharesAugust 4 stock options:5,600 shares+5 more
8 metrics
August 3 stock options63,011 sharesInducement award to new Chief Regulatory Officer
August 3 RSUs44,987 sharesInducement award to new Chief Regulatory Officer
August 4 stock options5,600 sharesInducement awards to two new employees
August 4 RSUs2,800 sharesInducement awards to two new employees
August 3 exercise price$32.23 per shareStock options granted August 3, 2026
August 4 exercise price$29.95 per shareStock options granted August 4, 2026
Option vesting period4 years25% vests on the first anniversary and the balance monthly thereafter
RSU vesting period4 years25% vests on each anniversary of August 20
"granted inducement awards consisting of non-qualified stock options to purchase"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
restricted stock unitsfinancial
"restricted stock units (RSUs) underlying 44,987 shares"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
nasdaq listing rule 5635(c)(4)regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
BRISBANE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 3, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 63,011 shares of Class A common stock and restricted stock units (RSUs) underlying 44,987 shares of Class A common stock to Nancy Bowman, M.D., Ph.D., Vera’s new Chief Regulatory Officer, under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan), and on August 4, 2026, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 5,600 shares of Class A common stock and RSUs underlying 2,800 shares of Class A common stock to two (2) new employees under the Inducement Plan.The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option granted on August 3, 2026 has an exercise price per share equal to $32.23, Vera Therapeutics’ closing trading price on August 3, 2026, and each stock option granted on August 4, 2026, has an exercise price per share equal to $29.95, Vera Therapeutics’ closing trading price on August 4, 2026.Each stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. Each of the RSU awards will vest over four years, with 25% of the underlying shares vesting on each anniversary of August 20, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
AboutVera Therapeutics Vera Therapeutics is a commercial-stage biotechnology company focused on the pursuit of truth in science to transform medicine in autoimmune disease, starting with the kidney. Vera Therapeutics’ flagship commercial product is TRUTAKNA™ (atacicept-vymj), a B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) inhibitor. Vera Therapeutics is evaluating multiple diseases where the reduction of autoantibodies through inhibition of BAFF and APRIL may prove clinically meaningful. Vera Therapeutics was founded in 2016 and is based in Brisbane, California. To learn more, visit www.veratx.com.
What inducement equity grants did Vera Therapeutics (VERA) announce on August 7, 2026?
Vera Therapeutics announced Nasdaq Rule 5635(c)(4) inducement grants of stock options and RSUs to three new employees. According to Vera Therapeutics, these include options for 68,611 shares and RSUs for 47,787 shares of Class A common stock under the 2024 Inducement Plan.
How many Vera Therapeutics (VERA) shares were granted to the new Chief Regulatory Officer in August 2026?
Vera Therapeutics granted its new Chief Regulatory Officer options for 63,011 shares and RSUs for 44,987 shares. According to Vera Therapeutics, these inducement awards were approved on August 3, 2026, under the 2024 Inducement Plan as part of her employment package.
What are the exercise prices for the Vera Therapeutics (VERA) inducement stock options granted in August 2026?
The inducement options have exercise prices of $32.23 and $29.95 per share. According to Vera Therapeutics, $32.23 matches the August 3, 2026 closing price, and $29.95 matches the August 4, 2026 closing price for its Class A common stock.
How do Vera Therapeutics (VERA) inducement stock options granted in August 2026 vest?
The inducement stock options vest over four years, with 25% after one year and the rest monthly. According to Vera Therapeutics, remaining shares vest monthly over 36 months, contingent on each new employee’s continued service with the company.
What is the vesting schedule for Vera Therapeutics (VERA) RSU inducement awards granted in August 2026?
The RSU inducement awards vest over four years in equal annual installments. According to Vera Therapeutics, 25% of the underlying shares vest on each anniversary of August 20, subject to the recipient’s continued service through each vesting date.
Why did Vera Therapeutics (VERA) use Nasdaq Listing Rule 5635(c)(4) for these August 2026 grants?
Vera Therapeutics used Nasdaq Listing Rule 5635(c)(4) to grant equity as an inducement to employment. According to Vera Therapeutics, the Compensation Committee approved these stock options and RSUs as inducement awards material to hiring the new employees.
